Regulatory Affairs Services Provider in Czech Republic
DDReg provides pharmaceutical regulatory services in Czech Republic for medicine, medical device, and biologics companies. Our consultants manage SÚKL registration submissions across national, mutual recognition, decentralised, and centralized procedures; coordinate pricing and reimbursement applications under Act No. 48/1997; and maintain post-authorisation compliance for products throughout the Czech market lifecycle.
Czech Republic Regulatory Framework for Medicines and Medical Devices
The State Institute for Drug Control (SÚKL; Státní ústav pro kontrolu léčiv) is the national competent authority (NCA) for human medicinal products in the Czech Republic. SÚKL operates as an administrative body reporting to the Ministry of Health, with its registered office at Šrobárova 48, Prague 100 41. The Institute grants marketing authorisations, sets maximum manufacturer prices, determines reimbursement conditions, issues GMP and GDP certificates, oversees pharmacovigilance, and regulates pharmaceutical advertising.
The primary legislative basis for medicinal products is Act No. 378/2007 Coll., on Pharmaceuticals (zákon o léčivech), supplemented by Decree No. 228/2008 Coll. on marketing authorisation of medicinal products. SÚKL's pricing and reimbursement mandate derives from Act No. 48/1997 Coll. on Public Health Insurance, under which SÚKL publishes the List of Prices and Reimbursements for Medicinal Products updated monthly. Medical devices are governed by Act No. 375/2022 Coll. on medical devices and in vitro diagnostic medical devices, implementing EU MDR 2017/745 and IVDR 2017/746 into Czech national law.
Czech Republic ranked 7th in Europe in the 2024 EFPIA W.A.I.T. indicator for time from EMA opinion to patient access — evidence of comparatively efficient post-authorisation market entry. SÚKL participates actively in EU network procedures and contributes assessors to EMA scientific committees. The EU–US mutual recognition agreement for GMP inspections covers Czech Republic, confirming SÚKL's inspection capability at a level equivalent to FDA standards.
Regulatory Authorities in Czech Republic
| Authority | Role |
|---|---|
| SÚKL (State Institute for Drug Control) | National competent authority for human medicinal products; grants marketing authorisations; sets maximum prices; determines reimbursement; issues GMP/GDP certificates; oversees pharmacovigilance and pharmaceutical advertising |
| Ministry of Health | Policy and legislative oversight; issues Czech Pharmacopoeia; price regulation for medical devices via Ministry of Health Price Regulation 1/2024/OLZP; supervises SÚKL |
| EMA | EU central authority; SÚKL contributes Czech assessors to CHMP and other scientific committees; mandatory for ATMPs, biotechnology products, and specified new active substances |
| Czech Ethics Committees (AMOS system) | Multicentre clinical trial ethics review; coordinated through the AMOS national system; required alongside SÚKL clinical trial authorisation |
Regulatory Consulting in Czech Republic - Services Portfolio
DDReg's pharmaceutical regulatory services in Czech Republic cover the full product lifecycle across medicines, medical devices, biologics, and advanced therapies.
-
Marketing Authorisation - Pharmaceuticals
-
SÚKL Code Management and Labelling
-
Pricing and Reimbursement
-
Medical Devices and IVDs
-
Clinical Trials
-
Post-Authorisation Lifecycle Management
SÚKL Registration Services Czech Republic - Submission Process
DDReg manages Czech Republic regulatory submissions through structured phases:
-
Pre-Submission Strategy
-
Dossier Preparation
-
SÚKL Scientific Assessment
-
Marketing Authorisation and SÚKL Code Activation
-
Pricing, Reimbursement, and Post-Authorisation Compliance
Assessment timelines follow EU regulatory framework standards. Clock stops for applicant responses are excluded from the active assessment period:
| Procedure | Assessment Period |
|---|---|
| National Procedure (pharmaceuticals) | 210 days (excl. clock stops) |
| Mutual Recognition Procedure - RMS phase | 90 days |
| Mutual Recognition Procedure - CMS phase | 90 days |
| Decentralised Procedure (DCP) | 210 days (RMS + CMS combined) |
| Centralised Procedure (EMA) | 210 days (CHMP opinion) |
| Type IA variation | 30 days (notification) |
| Type IB variation | 30 days (assessment) |
| Type II variation | 60 days (up to 90 days with extension) |
| Medical device - ISZP notification (reimbursement listing) | 4 months from error-free notification |
| Pricing (maximum manufacturer price) | 90 days from complete application |
| Reimbursement listing (standard) | 75 days from complete application |
| Reimbursement listing (innovative product with CEA/BIA) | 180 days from complete application |
Note: Clock stop periods for question list responses add to calendar time. SÚKL requires fees paid in Czech Crowns before submission; delayed payments extend the effective start date. Market access speed post-authorisation is confirmed by Czech Republic's 7th-place EU ranking in the 2024 EFPIA W.A.I.T. indicator.
Czech Republic Regulatory Affairs Partner - DDReg's Expertise
The SÚKL code system is a Czech-specific identification mechanism that runs from submission through market supply reporting, reimbursement determination, and pharmacovigilance solutions. DDReg manages SÚKL code allocation, blue-box label preparation (with correct 'SÚKL kód:' notation format), code status transitions from 'B' to 'R' following variations, and ISZP notification workflows for medical devices.
Companies holding national Czech authorisations seeking to include Czech Republic in an MRP can maintain the same product name, marketing authorisation number, and SÚKL codes under SÚKL's REG-80 procedure provided the legal basis is identical and the original national MA is revoked from the date the MRP authorisation issues. DDReg manages REG-80 applications, the Day 60/90 timing of revocation requests, and pack size status handling where non-MRP presentations revert to status 'B' with a 180-day sell-through window.
SÚKL holds dual authority marketing authorisation and pricing/reimbursement making Czech Republic unusual among EU member states. DDReg coordinates both tracks in parallel: maximum manufacturer price application timing relative to marketing authorisation, CEA and BIA preparation for innovative products, and reimbursement category positioning. For medical devices, DDReg manages ISZP reimbursement notifications and compliance with Ministry of Health Price Regulation 1/2024/OLZP limits.
Section 33(2) of Act No. 378/2007 requires quarterly supply reporting by SÚKL code to SÚKL's electronic interface, a domestic-specific obligation that catches many foreign MAHs off-guard. DDReg establishes authenticated SÚKL IT system access for MAHs, sets up reporting workflows per SÚKL code, and manages the legal exposure created by non-reporting, which constitutes an administrative offence under Act No. 378/2007 with fines up to CZK 20,000,000.
Czech-language SmPC, PIL, and labelling are mandatory for national market placement. DDReg provides Czech-language regulatory medical writing for Module 1 national documents, foreign-language batch applications, and patient information materials. Where supply urgency requires placing non-Czech labelled batches, DDReg prepares the CZK 4,500 (code R-012) fee application and coordinates SÚKL approval.
Global Reach Explorer
Find Your Solution
Our Regulatory Affairs Consulting Services in Czech Republic portfolio covers:
Regulatory Strategies
The pharmaceutical industry operates under stringent regulations to ensure the safety, efficacy, and quality...
New Product Marketing Authorizations
Navigating marketing authorization is a complex and time-sensitive process. Every country has its own regulatory framework...
Gap Analysis and Remediation
In the highly regulated pharmaceutical industry, maintaining compliance is critical. Regulatory gap analysis helps identify deficiencies in technical documentation...
Regulatory Due Diligence
Regulatory issues arise unexpectedly and can create significant strain on a company’s resources. As such, it is advisable for all companies to carry out regular and frequent regulatory due diligence and audits...
API & DMF services
Drug Master Files (DMFs) contain confidential and detailed information regarding API processes—from manufacturing to storage. DDReg’s DMF Services deliver precise...
CMC Advisory
DDReg’s CMC services are dedicated to assisting customers in developing robust and an efficient regulatory strategy through all development phases - authoring...
Post Approval Life Cycle Management
Maximize product value with expert pharma lifecycle management. Our dedicated team ensures that your product remains on shelves and compliant with ever-evolving regulations through strategic post-approval management...
Certification Services
Partner with DDReg to navigate the complex process of regulatory certification of pharmaceutical...
ANDA and MA Holder Services
Our comprehensive services support both Abbreviated New Drug Applications (ANDA) and Marketing Authorization processes.
Publishing & Submission
Our comprehensive digital solution transforms traditional paper dossier submissions into a streamlined electronic format. With robust infrastructure and cutting‐edge management processes...
